

4 2006

Commissioner for Patents United States Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450

Grover F. Fuller, Jr. Pfizer, Inc. Legal Division 235 East 42nd Street New York NY 10017-5755

In Re: Patent Term Extension Application for U.S. Patent No. 4,831,031

Dear Mr. Fuller:

A certificate under 35 U.S.C. § 156 is enclosed extending the term of U.S. Patent No. 4,831,031 for a period of 5 years. While a courtesy copy of this letter is being forwarded to the Food and Drug Administration (FDA), you should directly correspond with the FDA regarding any required changes to the patent expiration dates set forth in the Patent and Exclusivity Data Appendix of the Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) or in the Patent Information set forth in the Green Book (FDA Approved Animal Drug Products). Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from FDA's Electronic Forms Download Website: http://www.fda.gov/opacom/morechoices/fdaforms/FDA-3542.pdf).

Inquiries regarding this communication should be directed to Mary C. Till by telephone at (571) 272-7755, or by e-mail at mary.till@uspto.gov.

Kery A. Fries

Senior Legal Advisor

Office of Patent Legal Administration
Office of the Deputy Commissioner

for Patent Examination Policy

cc:

Office of Regulatory Policy

HFD - 13 5600 Fishers I a

5600 Fishers Lane Rockville, MD 20857

Attention: Beverly Friedman

RE: GEODON® (ziprasidone HCl monohydrate)

FDA Docket No.: 03E-0259

## UNITED STATES PATENT AND TRADEMARK OFFICE

## (12) CERTIFICATE EXTENDING PATENT TERM UNDER 35 U.S.C. § 156

(68) PATENT NO. : 4,831,031

(45) ISSUED : May 16, 1989

(75) INVENTOR : John A. Lowe, III, et al.

(73) PATENT OWNER : Pfizer Inc.

(95) PRODUCT : GEODON® (ziprasidone HCl monohydrate)

This is to certify that an application under 35 U.S.C. § 156 has been filed in the United States Patent and Trademark Office, requesting extension of the term of U.S. Patent No. 4,831,031 based upon the regulatory review of the product GEODON® (ziprasidone HCl monohydrate) by the Food and Drug Administration. Since it appears that the requirements of the law have been met, this certificate extends the term of the patent for the period of

(94) Five years

from March 2, 2007, the original expiration date of the patent, subject to the payment of maintenance fees as provided by law, with all rights pertaining thereto as provided by 35 U.S.C. § 156(b).



I have caused the seal of the United States Patent and Trademark Office to be affixed this 3rd day of May

Stephen M. Pinkos

2006.

Acting Under Secretary of Commerce for Intellectual Property and Acting Director of the United States Patent and Trademark Office